PMID- 18370849
OWN - NLM
STAT- MEDLINE
DCOM- 20080423
LR  - 20131121
IS  - 1462-2416 (Print)
IS  - 1462-2416 (Linking)
VI  - 9
IP  - 2
DP  - 2008 Feb
TI  - Pharmacogenetic information derived from analysis of HLA alleles.
PG  - 207-14
LID - 10.2217/14622416.9.2.207 [doi]
AB  - A large amount of pharmacogenetic information has, in particular, accumulated on 
      the association between human leukocyte antigen (HLA) alleles and 
      hypersensitivity to certain drugs. Prospective HLA typing has dramatically 
      reduced the risk of abacavir hypersensitivity because of its strong association 
      with HLA-B*5701. Significant predisposition to nevirapine hypersensitivity has 
      been reported in Caucasian Australians harboring HLA-DRB1*0101 with high CD4+ 
      T-cell counts, and Sardinians and Japanese harboring HLA-Cw8. A strong 
      association between carbamazepine hypersensitivity and HLA-B*1502 has been 
      reported in Han Chinese. Most Han Chinese individuals with allopurinol-induced 
      severe cutaneous adverse reactions are positive for HLA-B*5801. HLA typing can 
      stratify risk of hypersensitivity to certain drugs and allow personalized 
      treatment, although the patients should be monitored closely even if they are 
      negative for HLA alleles associated with hypersensitivity.
FAU - Gatanaga, Hiroyuki
AU  - Gatanaga H
AD  - AIDS Clinical Center, International Medical Center of Japan, 1-21-1 Toyama, 
      Shinjuku-ku, Tokyo 162-8655, Japan. higatana@imcj.acc.go.jp
FAU - Honda, Haruhito
AU  - Honda H
FAU - Oka, Shinichi
AU  - Oka S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA Antigens)
RN  - 99DK7FVK1H (Nevirapine)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Alleles
MH  - Animals
MH  - Anti-HIV Agents/adverse effects
MH  - Dideoxynucleosides/adverse effects
MH  - Drug Hypersensitivity/genetics
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Nevirapine/adverse effects
MH  - *Pharmacogenetics
RF  - 77
EDAT- 2008/03/29 09:00
MHDA- 2008/04/24 09:00
CRDT- 2008/03/29 09:00
PHST- 2008/03/29 09:00 [pubmed]
PHST- 2008/04/24 09:00 [medline]
PHST- 2008/03/29 09:00 [entrez]
AID - 10.2217/14622416.9.2.207 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2008 Feb;9(2):207-14. doi: 10.2217/14622416.9.2.207.